<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02315157</url>
  </required_header>
  <id_info>
    <org_study_id>14D.244</org_study_id>
    <secondary_id>2014-009</secondary_id>
    <nct_id>NCT02315157</nct_id>
  </id_info>
  <brief_title>Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma</brief_title>
  <official_title>Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Cancer Center at Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of bendamustine hydrochloride in
      treating patients with previously treated multiple myeloma. Drugs used in chemotherapy, such
      as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells,
      either by killing the cells, by stopping them from dividing, or by stopping them from
      spreading.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To identify a maximum tolerated dose of bendamustine (bendamustine hydrochloride) in
      patients with multiple myeloma.

      SECONDARY OBJECTIVES:

      I. To evaluate the safety of escalating doses of bendamustine in patients with multiple
      myeloma.

      II. To describe the response after bendamustine

      OUTLINE: This is a dose-escalation study.

      Patients receive bendamustine hydrochloride intravenously (IV) over 60-180 minutes on days 1
      and 2.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn by PI
  </why_stopped>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of bendamustine</measure>
    <time_frame>2 days</time_frame>
    <description>Defined as the dose where no more than 1 out of 6 patients experience dose-limiting toxicities. Toxicities will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity (NCI CTCAE version 4.0)</measure>
    <time_frame>Up to 92 days following the last administration of study treatment</time_frame>
    <description>Graded according to NCI CTCAE version 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Plasma Cell Leukemia</condition>
  <arm_group>
    <arm_group_label>Bendamustine 200 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 400 mg/m2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bendamustine 250 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bendamustine hydrochloride IV over 60-180 minutes on days 1 and 2 (total dose 500 mg/m2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Bendamustine 200 mg/m2</arm_group_label>
    <arm_group_label>Bendamustine 250 mg/m2</arm_group_label>
    <other_name>Treakisym</other_name>
    <other_name>Ribomustin</other_name>
    <other_name>Levact</other_name>
    <other_name>Treanda</other_name>
    <other_name>SDX-105</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with multiple myeloma who have not achieved a CR following at least 4 cycles
             of induction therapy

          2. Age up to 80 years

          3. ECOG Performance Status of 0 or 1

          4. Left ventricular ejection fraction =/&gt; 40%. No uncontrolled arrhythmias or symptomatic
             cardiac disease

          5. FEV1, FVC and DLCO =/&gt; 40%. No symptomatic pulmonary disease.

          6. Serum bilirubin &lt;2 x upper limit of normal, alkaline phosphatase &lt;3 x upper limit of
             normal. No evidence of chronic active hepatitis or cirrhosis. No effusion or ascites &gt;
             1 L prior to drainage.

          7. HIV negative

          8. Negative beta HCG test in woman with child bearing potential, defined as not
             post-menopausal for 12 months or no previous sterilization

          9. Patients or guardian able to sign informed consent

         10. Availability of previously collected autologous stem cells (at least 3.0 x 106 CD34
             cells/kg)

         11. Calculated GFR &gt; 50 ml/minute

        Exclusion Criteria:

          1. Patients with uncontrolled hypertension (systolic &gt; 140, diastolic &gt; 90 despite
             antihypertensive therapy

          2. Patients with uncontrolled bacteria, viral or fungal infections (currently taking
             medication and progression of clinical symptoms)

          3. New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina,
             severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities

          4. Relapsed/refractory myeloma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Sidney Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://hospitals.jefferson.edu/</url>
    <description>Jefferson University Hospitals</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2014</study_first_posted>
  <last_update_submitted>October 19, 2016</last_update_submitted>
  <last_update_submitted_qc>October 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Partial Response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

